Trading update

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, provides the following unaudited trading update for the six months ended 30 June 2025.

• Gross revenue up 102% to £557K (H1 2024: £276K)
• Gross profit up 173% to £303K (H1 2024: £111K)
• Gross profit margin increased to 54% (H1 2024: 40%)
• Other administrative costs (including selling, R&D and patent costs and excluding shared based payments and depreciation) remain stable at £1.14m (H1 2024: £1.07m)
• Strong cash balance of £1.3m (H1 2024: £1.2m)
• Growing list of new customers

ü 30 new customers in Asia in 2025

ü Ecommerce customers in H1 2025 up by 38% to 5,095 (H1 2024: 3,702)

ü Launch of products in the USA with two new partners and first order received from a leading USA weight management brand looking to launch in H2 online and subsequently in Walmart USA

ü New six metric tonne order received and shipped from Brenntag in H1 2025, the Company's new Australian distributor

The Company has made strong financial progress in H1 2025 with sales growing at an increased momentum at more than double H1 2024 and at an improved margin. We anticipate continued solid momentum in sales growth with the full year effect of 2024 launches, new and existing partners launching new products in USA and Asia, ecommerce continuing its growth trajectory with launch of products on Amazon India, and annual license revenues from SweetBiotix occurring in H2 2025.

The Company should see an effect of its reductions in PR, broker, and staff costs in H2 2025 and a recently negotiated 30% reduction in IP costs. Whilst margins will vary according to the revenue mix, the Company expects continued margin improvements with the removal of the stock overhang outlined in the full year accounts, reductions in the cost of goods from volume discounts, and supplying Asia from India, which has lower manufacturing costs.

With sales growing strongly, and significant further product opportunities still in the pipeline, the Board is confident that OptiBiotix has the potential to deliver substantial growth in shareholder value in the years ahead.

Stephen O'Hara, CEO of OptiBiotix Health plc said: "The strong growth in 2024 has continued at an increased momentum into H1 2025 with sales growth across all areas of business. Equally important are the changes we made to reduce costs and improve margins whilst growing our top line which are beginning to impact positively on gross profit and should have a greater impact in H2 and into 2026.

"Our investments in sales and marketing are starting to deliver a multi-channel, multi territory revenue stream, reducing reliance on a single partner or territory. Regulatory approvals and health claims have now been approved in all major territories and a network of global manufacturing and distribution partners established. This gives the Company a broad base on which to deliver future revenue growth. As the impact of the Company reducing costs takes full effect, it continues to grow its top line and improve margins with the aim of achieving profitability across all parts of the business and the Group generating positive cashflow."